Introduction {#s1}
============

Psoriasis is a chronic, inflammatory disease involving skin of genetically predisposed individuals. It affects approximately 2% of the general population, with \>50% of patients presenting in the first three decades of life ([@B17]; [@B45]; [@B24]). There is a wide spectrum of cutaneous manifestations of psoriasis, with individual lesions varying from pinpoint to large plaques, or even generalized erythroderma ([@B45]). The most common and well-recognized morphological presentation of psoriasis is the plaque type. These lesions reflect skin inflammation, epidermal hyperplasia, and angiogenesis, as consequence of a dysregulation of skin immune responses ([@B45]; [@B57]). However, altered immunity can operate systemically and signs of inflammation can readily be detected at areas outside the skin. As a result, in psoriatic patients, inflammation is widespread, and, in most cases, different comorbid conditions co-exist ([@B14]; [@B7]; [@B87]; [@B16]). Among them, cardio-vascular diseases (CVD) are importantly associated to psoriasis, together with diabetes mellitus and metabolic disorders, including obesity, hypertension, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD) ([@B6]; [@B53]; [@B7]; [@B8]; [@B28]; [@B10]; [@B20]; [@B87]). Also inflammatory bowel diseases (IBD) and kidney diseases, as well as infections, depression, and cancer are often comorbid conditions that can be developed in psoriatic patients ([@B13]; [@B14]; [@B94]). To date, it is still controversial whether the chronic inflammatory nature of psoriasis is a contributing factor or an independent risk factor for the development of these comorbidities. Consistently, inflammatory arthritis, that frequently affects small joints of psoriatic patients, could be considered either as an extracutaneous manifestation of psoriasis or as a separate entity, and thus a comorbidity ([@B43]). Among the comorbid conditions, cardiovascular and metabolic diseases are of particular importance, as they may considerably reduce life expectancy of psoriatic patients, especially of those affected by the most severe forms of the disease ([@B7]; [@B79]).

This review summarizes the evidence on the pathophysiological relationship between psoriasis and its comorbidities, with emphasis on cardio-metabolic comorbid conditions. The ability of biologic therapies to reduce systemic inflammation and to ameliorate comorbidities, including reducing cardiovascular risk, in patients with psoriasis will be also discussed.

Pathogenesis of Chronic Plaque Psoriasis {#s2}
========================================

Primary cause of psoriasis is a dysregulation of immune responses, which manifests in individuals carrying one or more psoriasis susceptibility genes, either skin specific or related to immune functions, and after their exposure to certain environmental triggers ([@B68]; [@B71]; [@B31]). The latter include physical trauma (Koebner phenomenon) and infections, which trigger innate immune responses by promoting the formation and the release of nucleic acid/autoantigen complexes by injured skin cells. In particular, complexes formed by the cathelecidin LL37 and self-DNA/RNA fragments activate plasmacytoid dendritic cells (pDCs), a subset of DC releasing high IFN-α and TNF-α ([@B67]; [@B52]) pDC recruitment in psoriatic skin is determined by the chemokine chemerin, and correlates with the massive presence in the mid-papillary dermis of other innate immune cells, such as neutrophils, macrophages, monocytes, and mast cells ([@B3]). Local production of IFN-α and other type I IFNs induces keratinocyte immune activation and maturation of myeloid DCs (mDCs), with consequent beginning of the adaptive immune response phase. As a consequence, a IL-23/IL-17 inflammatory environment is established in psoriatic skin, with DC and macrophage-derived IL-23 promoting the type 17 helper (Th17) and cytotoxic (Tc17) cell effector functions ([@B56]; [@B40]). In parallel, mDCs induce the IL-12/IFN-γ cytokine axis, which is responsible for the strong type II IFN transcriptomic signature and the high frequency of Th1 and Tc1 cells in both psoriasis plaques and peripheral blood of patients ([@B81]; [@B11]). The innate lymphoid cells (ILC), a class of immune cells bearing lymphoid morphology, but no immune cell lineage markers ([@B82]; [@B12]), together with γδ-T cells, an innate-like T-cell population involved in surveillance of epithelial surfaces, are also critical contributors to plaque development by releasing considerable levels of IL-17 and IL-22 ([@B92]). Also mast cells and neutrophils can represent an innate sources of IL-17 in psoriatic skin ([@B54]).

Following the massive expansion of effector immune cells in both the epidermis and dermis, very high levels of IL-17 and IL-22 are produced. These two cytokines, together, mediate most of the epidermal hyperplasia by impairing differentiation of keratinocytes, and inducing their premature maturation and aberrant cornification ([@B69]). IL-17 also functions by activating keratinocytes to produce neutrophil- and T-cell-recruiting chemokines, namely CXCL1/CXCL2/CXCL8 and CCL20, respectively, as well as antimicrobial peptides (AMP), including LL37 and S100 family members ([@B2]; [@B95]). Thus, IL-17 is central in a pathogenic loop linking T cells and keratinocytes. On the other hand, the T-cell-derived IFN-γ and TNF-α activate a plethora of inflammatory pathways in resident skin cells, in particular keratinocytes and endothelial cells ([@B1]; [@B4]). Each cytokine regulates distinct responses with a certain degree of synergism in getranscription factor regulating gene ene expression induction/inhibition. Most of the effects induced by IFN-γ are potentiated by TNF-α, which intracellularly activates NF-κB, a transcription factor regulating gene expression frequently in collaboration with the signal transducer and activator of transcription (STAT)1 induced by IFN-γ. TNF-α induces expression of ICAM-1 on resident skin cells, permitting the adhesion and extravasation of circulating leukocytes. Moreover, TNF-α stimulates the production of several chemokines active on immune cells, as well as pro-inflammatory cytokines, in particular IL-6 and IL-1, which sustain Th17 expansion ([@B4]; [@B26]). Importantly, TNF-α, together with IL-17, induces IL-36γ in psoriasis lesions, which in turn promotes expression of AMP and chemokines recruiting neutrophils and Th17 cells, as well as interferes with terminal differentiation and cornification process of the epidermis ([@B22]). Interestingly, transcriptional profiling studies conducted on lesional psoriatic skin showed that the IFN-γ-signature predominates, even though IL-17 and TNF-α also potently induce a vast panel of genes ([@B69]; [@B25]). Although studies demonstrated a central role of IL-22 in psoriasis pathogenesis by activating STAT3-dependent genes involved in differentiation and proliferation processes, this cytokine induces a limited panel of genes compared to IL-17, as detected in human lesional psoriatic skin ([@B25]). Importantly, intrinsic or genetic alterations of keratinocytes in the activation of key signaling pathways induced by pro-inflammatory cytokines (i.e., STAT1 and STAT3, NF-κB, ERK1/2, and Act1) may be responsible for the typical unbalance between proliferation and differentiation processes, as well as inflammatory signatures observed in psoriatic epidermis ([@B46]; [@B21]).

Collectively, a pathogenic cross-talk between DCs, T cells, and keratinocytes, sustained by type I IFNs, IL-23, IL-12, IFN-γ, IL-17, TNF-α, and IL-22, and possibly supported by other immune cell players, causes keratinocyte production of pro-inflammatory molecules, as well as concurs to derange proliferative and differentiative programs of the epidermis. This becomes a self-amplifying loop, where these products and altered homeostasis act back on T cells and DC to perpetuate the cutaneous inflammatory processes.

Comorbidities of Chronic Plaque Psoriasis {#s3}
=========================================

Since 1897, when Strauss reported an association between psoriasis and diabetes, emerging epidemiologic studies find additional associations between psoriasis and inflammatory diseases, apart from well-known psoriatic arthritis (PsA) ([@B83]). The association between psoriasis and inflammatory diseases is stronger in the most severe forms of psoriasis ([@B87]). Comorbidity psoriasis burden includes mainly CVD, metabolic disorders, such as diabetes, dyslipidemia, and metabolic syndrome, inflammatory bowel disease, and kidney disease. The prevalence of traditional CV risk factors such as hypertension, obesity, diabetes, dyslipidemia, metabolic syndrome, and cigarette smoking is increased in patients with psoriasis compared to controls ([@B41]).

Patients with psoriasis are more frequently overweight or obese ([**Figure 1**](#f1){ref-type="fig"}). Obesity, but also BMI, hip circumference and waist-hip ratio are independent risk factors for psoriasis. The risk was found to increase with obese severity, as higher body mass index (BMI) ([@B51]). A meta-analysis of 16 observational studies found a pooled OR of 1.66 for the association between the two diseases (95% CI 1.46--1.89) ([@B6]). A cross-sectional study found a direct correlation between psoriasis severity and obesity ([@B33]). As obesity, also hypertension is prevalent among psoriatic patients compared to those who are not affected. A meta-analysis of 24 studies showed a pooled OR of 1.58 (95% CI 1.42--1.76) for the association between hypertension and psoriasis ([@B8]). Poor controlled and sever hypertension appear to increase with more severe disease ([@B53]). Psoriasis is an independent risk factor for diabetes, with higher risk with greater severity of psoriasis ([@B86]). Diabetic patients with psoriasis appear to be more likely to suffer from micro and macro-vascular complications, compared to patients without psoriasis. The pooled OR for psoriasis associated with diabetes in a meta-analysis of 44 studies was 1.76 (95% CI 1.59--1.96) ([@B28]). Atherogenic lipid profile and reduced high density lipoprotein (HDL) were reported among patients with psoriasis, compared to patients without psoriasis. Dyslipidemia may be more prevalent in psoriatic patients. In a systematic review, most of the studies found significant association between psoriasis and dyslipidemia, with OR ranging between 1.04 and 5.55 ([@B59]). Higher odds of dyslipidemia were reported in severe psoriasis, compared to patients with mild disease. According to some studies, dyslipidemia may be a risk factor for developing psoriasis ([@B97]). Metabolic syndrome comprises a group of well-known cardiovascular (CV) risk factors, including central obesity, hypertension, insulin resistance, and dyslipidemia. A cross-sectional study reported that the prevalence of metabolic syndrome correlated directly with psoriasis body surface area ([@B53]). A meta-analysis of 12 studies found a pooled OR of 2.26 (95% CI 1.70--3.01) for the association with psoriasis ([@B9]). The analysis of the separate components of metabolic syndrome showed the strongest association between obesity, suggesting that the adiposity is the main factor in the association between psoriasis and metabolic syndrome.
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Although both CV risk factors and CVD are prevalent among psoriatic patients, psoriasis is an independent risk factor for the latters. A large cohort study found that psoriasis is an independent risk for myocardial infarction (MI), also considering other traditional CV risk factors ([@B39]). Two meta-analyses showed that the risks of MI, stroke, and death caused by CVD, collectively termed as major cardiovascular events, is greatest among patients with psoriasis and appear to be greatest among those with severe or longer duration disease ([@B7]; [@B79]). Psoriasis, as an independent CV risk factor, was reported to strongly impact on the Framingham Risk Score for more than 60% of the patients ([@B62]).

The epidemiology of the relationship between IBD and psoriasis is still unclear. Many studies reported that psoriasis may be associated with an increased incidence and prevalence of IBD (and *vice versa*), in particular Crohn\'s disease ([@B13]; [@B27]). Psoriasis may be more strongly associated with Crohn\'s disease than ulcerative colitis withOn the other hand, the T-cell-derived ORs of 2.49 (95% CI 1.71--3.62) *versus* 1.64 (95% CI 1.15--2.23), respectively ([@B62]). Patients with psoriasis and concomitant IBD have a higher rate of comorbidities (seronegative arthritis, thyroiditis, diabetes, and lymphoma) than patients with only psoriasis ([@B14]). Considering the potentially hepatotoxicity and nephrotoxicity of many psoriatic treatments, there is a great interest in the epidemiology of liver and renal disease in psoriatic patients. NAFLD is a common liver disease comprising mild forms of steatosis up to steato-hepatitis. Psoriasis is frequently associated to metabolic disorders that can favor liver steatosis. The prevalence of NAFLD among patients with psoriasis is greater compared with non-psoriatic patients, but the evidence of the association between psoriasis and hepatic diseases is based on seven low-to-moderate quality observational studies with pooled OR of 2.15 (95% CI 1.57--2.94) ([@B20]). Moderate-to-severe psoriasis may be an independent risk factor for chronic kidney disease (CKD) and end-stage renal disease. A cohort study found that severe psoriasis may be associated with CKD and end-stage renal disease with HRs of 1.93 (95% CI 1.79--2.08) and 4.15 (95% CI 1.70--10.11), respectively ([@B94]).

Several studies have reported association between psoriasis and other emerging comorbidities such as cancer, especially T-cell lymphoma, mood disorders, pneumopathies such as chronic pulmonary disease and obstructive sleep apnea, peptic ulcer disease, hyperuricaemia/gout, osteoporosis, and sexual dysfunction ([@B87]). Some of these need to be confirmed in larger studies.

Pathogenesis Behind the Comorbidities in Psoriasis {#s4}
==================================================

The pathogenesis behind psoriasis comorbidity remains partially unknown; however different factors may be involved, including common pattern of immune responses and inflammatory pathways, shared risk factors, and genetic predisposition ([@B87]) ([**Figure 2**](#f2){ref-type="fig"}).
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Patients with psoriasis are enriched for certain common genetic variants (HLA, FUT2, UBE2L3, SH2B3) that predispose to increased risk of dyslipidemia, hypertension, and CVD ([@B58]).

Most common inflammatory pathways between psoriasis and its comorbidities strictly depends on the expansion of circulating pathogenic T cells, instructed by DC activated at skin sites, and to the establishment of systemic inflammation. These pathways involve key cytokines and signal transducers, such as IL-23R, IL-12B, IL-21, IL-4, and IL-5, in psoriatic arthritis; IL-23R, IL-12B, IL-13, Rel, TYK2, and JAK2 in Crohn\'s disease ([@B36]; [@B38]; [@B91]). In addition to common cytokine hallmarks, psoriasis and cardiometabolic diseases may share other mutations, such as CDKAL1 and apolipoprotein E ([@B35]).

A high number of studies have shown that psoriasis and cardiometabolic disorders have rather more commonly similar underlying immunologic mechanisms related to Th1 and Th17 cells activation ([@B55]). Inflammatory mediators released from psoriatic lesions, including TNF-α, IFN-α, IFN-γ, IL-1, IL-6, and IL-17, may have systemic effects contributing to atherogenesis. Consistently, recent studies conducted on human tissues showed that psoriasis and atherosclerosis exhibit significant overlap of their transcriptomes and in particular those dependent on TNF-α and IFN-γ, thus providing the linking between the two diseases ([@B63]). By contrast, IL-17A and CCL20 genes were higher in psoriasis than in atherosclerosis tissue, whereas IL-17R was expressed at comparable levels. Because of the link between IL-17 and neutrophil infiltration in atherosclerotic plaques and its pathogenic role in psoriasis, it has been suggested that the IL-17/neutrophil axis could take part to atherogenesis associated with psoriatic disease ([@B80]). Consistently, aortic vascular inflammation in psoriatic patients has been found to correlate with disease severity and high levels of S100A8/A9 neutrophil activation markers ([@B66]). In addition, the neutrophil extracellular traps (NET)osis, a defense mechanism operating in psoriasis and based on the formation of cytosolic granule proteins containing autoantigens, has been found to induce macrophage priming, Th17 activation, and immune cell recruitment in atherosclerosis similarly to psoriasis ([@B5]; [@B30]; [@B32]). NET are also shown to directly induce endothelial dysfunction and plaque rupture in human carotid plaque sections ([@B76]). Monocyte and neutrophil damage, increased oxidative stress, endothelial dysfunction, angiogenesis, and increased circulating micro particles are other common shared alterations ([@B76]). Psoriasis and atherosclerosis patients also share dysfunctional peripheral T regulatory (Treg) cells, a subset of T lymphocytes highly releasing TGFβ, IL-10, and IL-35, with inhibitory function on T cell activation and proliferation, and anti-inflammatory roles through endothelial cell modulation ([@B84]; [@B48]; [@B85]; [@B65]). In psoriasis, this impairment may be dependent on high IL-6 levels, as demonstrated by blocking IL-6 in co-cultures of Treg cells and effector T cells from psoriatic patients ([@B44]).

Systemic inflammation associated with psoriasis also promotes inflammation in the adipose tissue, which harbors cells and molecular components of the immunity system. Psoriatic adipose tissue contains immune cells that can influence cardiometabolic disease ([@B77]). Among them, T cells, DCs, neutrophils, mast cells, and adipose tissue macrophages contribute to obesity and insulin resistance, whereas eosinophils and Treg are protective. Obesity is also associated to systemic inflammation because of the release of adipokines, including chemerin, adiponectin, resistin, visfatin, C-reactive protein released by macrophages, and T cells infiltrating visceral adipose tissue. Adipokines can contribute to the pathogenesis of insulin resistance and fuel inflammation associated with psoriasis ([@B29]). Adipokines together with chemokines (i.e., CXCL8 and CCL2) produced by visceral adipose tissue can also contribute to progression of atherosclerosis and CDV disease development by influencing endothelial cell function and interaction with immune cells ([@B47]; [@B49]; [@B18]). An association between obesity and PsA has been confirmed, and the presence of metabolic syndrome and related adipokines correlates with skin and joint disease activity ([@B34]). However, levels of adipokines have been found to not differ between PsA patients with clinical evident psoriasis and PsA sine psoriasis, reinforcing the concept that metabolic manifestations during psoriatic disease may be independent of severity of cutaneous and articular involvement and are potentially related to the subclinical chronic inflammation ([@B23]). As abdominal visceral fat, also epicardial adipose tissue has been shown to be increased in patients with psoriasis, and potentially contribute to increased CV risk ([@B89]). Additionally, epicardial adipose tissue has been referred as potentially responsible for a distinctive pattern of CV disorders seen in psoriasis (accelerated coronary atherosclerosis leading to myocardial infarction; atrial myopathy leading to atrial fibrillation and thromboembolic stroke, and ventricular myopathy leading to heart failure with a preserved ejection fraction) ([@B70]). Psoriasis-related inflammation could trigger the progression from normal liver to NAFLD. Pro-inflammatory cytokines and adipokines, including TNF-α, play a pivotal role in pathogenesis of both psoriasis and NAFLD as well as in progression of NAFLD to NASH. Moreover, obesity induces a bio-mechanical stress that may be a possible trigger for PsA ([@B61]).

Finally, as psychosocial impact of psoriasis is relevant, this could favor unhealthy lifestyles, such as alcoholism and smoking habit that are well-known CV and metabolic risk factors. Anxiety, depression, and suicidal ideation and behavior (SIB) are prevalent in patient with psoriasis. There is growing evidence that inflammation is associated with pathophysiology of depression. Pro-inflammatory cytokines such as IL-1 and IL-6 are elevated both in psoriasis and depression. Cytokine-mediated systemic inflammation may be an underlying patho-mechanism of both psoriasis and mental health disorders, such as depression and SIB ([@B98]).

Systemic Treatment of Psoriasis Could Ameliorate Cardiovascular Comorbidities {#s5}
=============================================================================

New psoriasis treatment paradigms have gone beyond the belief of psoriasis as a disease limited to the skin. Borrowing the experience from the studies of other immune-mediated inflammatory diseases, such as Crohn\'s disease and rheumatoid arthritis, the goals of treating systemic inflammation in psoriasis are two: to prevent and even to reverse comorbidities ([@B88]; [@B50]).

Many surrogate laboratory and radiologic biomarkers of inflammation and endothelial dysfunction have been identified among patients with inflammatory conditions. These include C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), levels of glycoprotein acetylation, coronary flow reserve (CFR), flow-mediated dilatation, carotid intima media thickness, vascular inflammation measured through 18-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/TC) ([@B90]; [@B75]). For example, in patients with moderate to severe psoriasis treated with systemic therapies studies have reported reduction in ESR and/or CRP levels ([@B74]). A prospective study found that improvement in Psoriasis Area Severity Index (PASI) score *via* TNF-α inhibitors was associated with reduced aortic vascular inflammation measured using 18F-FDG PET/TC ([@B15]). A study on 37 patients treated with TNF-α inhibitors for an average of 6 months reported a significant increase in the value of CFR in the left anterior descending coronary ([@B73]). Recently, biologic therapy was shown to be associated with favorable modulation of coronary plaque indices by coronary computed tomography angiography in patients with severe psoriasis ([@B37]). There are some evidences in favor of the hypothesis that treating psoriasis with systemic agents could prevent CVD, as a result of suppression of systemic inflammation. In a recent meta-analysis in patients with psoriasis and PsA, systemic therapy was found to significantly decrease the risk of all cardiovascular events with a RR of 0.75 (95% CI 0.63--0.91). With the exception of methotrexate, there are no studies formally evaluating the effect of any anti-psoriatic therapy as a treatment for coronary heart disease ([@B78]). Two retrospective analysis of cardiovascular events rates in patients with psoriasis found that patients receiving rouTNF-α inhibitors had significant lower risks for MI compared with patients receiving topical therapies with OR 0.5 (95% CI 0.32--0.79) or phototherapy, HR 0.77 (95% CI 0.60--0.99) ([@B96]; [@B99]). Few studies found no significant differences in overall MI risk between patients treated with systemic therapies and those who received ultraviolet B phototherapy. In a randomize double-blind clinical trial adalimumab reduced key markers of inflammation including glycoprotein acetylation compared with phototherapy, with no effect on glucose metabolism and vascular inflammation ([@B64]). The protective cardiovascular effect could be not exclusive to TNF-α inhibitors. CARIMA study indicates that secukinumab might have a beneficial effect on cardiovascular risk by improving the endothelial function ([@B93]).

Obesity is accompanied by a dysregulation of adipocytokines and systemic inflammation and has a well-known effect on psoriasis severity and response to therapies. Current data suggest that weight loss improves psoriasis. Meta-analysis of three randomized control trials confirmed that weight loss following lifestyle interventions (diet or physical activity) improves psoriasis compared with reduction in the PASI score with a pooled mean difference of -2.49 (95% CI -3.90 to -1.08; *P* = 0.004) ([@B60]). Long-term weight loss in patients with psoriasis has long-lasting positive effects on the severity of psoriasis ([@B42]). A possible role for biologic agents in reducing obesity in psoriasis has not been observed to date. Although TNF-α inhibitors can induce modest weight gain, they do not cause an increase in visceral adipose tissue and thee association between low-carbohydrates calorie-restricted diet and anti-TNF-alpha therapy seems to be able to improve the anthropometric profile of psoriasis patients ([@B19]). No evidence of clinically weight gain has been observed in studies of ustekinumab or ixekizumab. Since IL-17A does not alter adipogenesis and/or insulin resistance mediated by an inflammatory environment and contributes only to the propagation of inflammation in human obese adipose tissues, anti-IL17A agents may play a beneficial effect in inflammatory pathologies, where obesity contributes to poorer response to biologic treatments ([@B72]).

Conclusions {#s6}
===========

Psoriasis is increasingly being recognized as a systemic inflammatory disorder affecting not only skin and joints. The association with metabolic disorders, such as diabetes, dyslipidemia, and metabolic syndrome, and CVD deserves special attention. Common genetics and shared immuno-inflammatory pathways may partially explain this association. Cutaneous lesions produce a wide range of inflammatory products that are released into systemic circulation and fuel the systemic inflammation. Other non-cutaneous sites, like adipose tissue, can contribute to the inflammatory state. Systemic therapies targeting psoriasis may prevent and even reverse cardio-metabolic comorbidities as a result of suppression of systemic inflammation. It is important for clinicians to recognize psoriasis comorbidity burden to ensure a comprehensive medical care for the patients. In the view of psoriasis as systemic inflammation disease new treatment paradigms may potentially reduce or prevent the comorbidities associated with systemic inflammation.
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